SCARLETRED is an international dermatology startup aiming on to generate novel products for highly demanded applications in the digital analysis and therapeutic treatment of skin diseases.

COMPANY PRODUCT AND R&D PORTFOLIO

SCARLETRED®Vision: The patented mobile medical device system enables objective skin documentation and analysis in (pre-)clinical trials and in skin care industry.

– Superoxide Dismutase: The anti-inflammatory acting biologics rhSOD is under clinical development to treat acute and non healing wounds in the orphan disease Epidermolysis bullosa (Butterfly Children).

SCARLETRED Holding GmbH
Campus-Vienna-Biocenter 5
1030 Vienna
Austria
Building: VBC5 – Map

Harald Schnidar, PhD, MBA

+43 (0) 664 410 94 04